Antiarrhythmic Medications

  • Anne M. Dubin


Cardiogenic Shock Heart Block Magnesium Sulfate Sick Sinus Syndrome Monitoring Parameter 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kim SY, Benowitz NL. Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide. Drug Saf 1990;5(6):393–420.PubMedCrossRefGoogle Scholar
  2. 2.
    Marcus FI. Pharmacokinetic interactions between digoxin and other drugs. J Am Coll Cardiol 1985;5(5 Suppl A):82A–90A.Google Scholar
  3. 3.
    Webb CL, Dick M 2nd, Rocchini AP, et al. Quinidine syncope in children. J Am Coll Cardiol 1987;9(5):1031–1037.PubMedGoogle Scholar
  4. 4.
    Benson DW Jr, Dunnigan A, Green TP, Benditt DG, Schneider SP. Periodic procainamide for paroxysmal tachycardia. Circulation 1985;72(1):147–152.PubMedGoogle Scholar
  5. 5.
    Woosley RL, Drayer DE, Reidenberg MM, Nies AS, Carr K, Oates JA. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N Engl J Med 1978;298(21):1157–1159.PubMedGoogle Scholar
  6. 6.
    Holt DW, Walsh AC, Curry PV, Tynan M. Paediatric use of mexiletine and disopyramide. Br Med J 1979;2(6203):1476–1477.PubMedCrossRefGoogle Scholar
  7. 7.
    Rosen MR, Hoffman BF, Wit AL. Electrophysiology and pharmacology of cardiac arrhythmias. V. Cardiac antiarrhythmic effects of lidocaine. Am Heart J 1975;89(4):526–536.PubMedCrossRefGoogle Scholar
  8. 8.
    Moak JP, Smith RT, Garson A Jr. Mexiletine: an effective antiarrhythmic drug for treatment of ventricular arrhythmias in congenital heart disease. J Am Coll Cardiol 1987;10(4):824–829.PubMedCrossRefGoogle Scholar
  9. 9.
    Garson A Jr, Kugler JD, Gillette PC, Simonelli A, McNamara DG. Control of late postoperative ventricular arrhythmias with phenytoin in young patients. Am J Cardiol 1980;46(2):290–294.PubMedCrossRefGoogle Scholar
  10. 10.
    Perry JC, McQuinn RL, Smith RT Jr, Gothing C, Fredell P, Garson A Jr Flecainide acetate for resistant arrhythmias in the young: efficacy and pharmacokinetics. J Am Coll Cardiol 1989;14(1):185–191; discussion 92–93.PubMedCrossRefGoogle Scholar
  11. 11.
    Wren C, Campbell RW. The response of paediatric arrhythmias to intravenous and oral flecainide. Br Heart J 1987;57(2):171–175.PubMedCrossRefGoogle Scholar
  12. 12.
    Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 1989;321(6):406–412.Google Scholar
  13. 13.
    Fish FA, Gillette PC, Benson DW Jr. Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. The Pediatric Electrophysiology Group. J Am Coll Cardiol 1991;18(2):356–365.PubMedCrossRefGoogle Scholar
  14. 14.
    Russell GA, Martin RP. Flecainide toxicity. Arch Dis Child 1989;64(6):860–862.PubMedCrossRefGoogle Scholar
  15. 15.
    Janousek J, Paul T, Reimer A, Kallfelz HC. Usefulness of propafenone for supraventricular arrhythmias in infants and children. Am J Cardiol 1993;72(3):294–300.PubMedCrossRefGoogle Scholar
  16. 16.
    Kates RE, Yee YG, Winkle RA. Metabolite cumulation during chronic propafenone dosing in arrhythmia. Clin Pharmacol Ther 1985;37(6):610–614.PubMedGoogle Scholar
  17. 17.
    Intravenous esmolol for the treatment of supraventricular tachyarrhythmia: results of a multicenter, baseline-controlled safety and efficacy study in 160 patients. The Esmolol Research Group. Am Heart J 1986;112(3):498–505.Google Scholar
  18. 18.
    Trippel DL, Wiest DB, Gillette PC. Cardiovascular and antiarrhythmic effects of esmolol in children. J Pediatr 1991;119(1 Pt 1):142–147.Google Scholar
  19. 19.
    Pickoff AS, Zies L, Ferrer PL, et al. High-dose propranolol therapy in the management of supraventricular tachycardia. J Pediatr 1979;94(1):144–146.PubMedCrossRefGoogle Scholar
  20. 20.
    Trippel DL, Gillette PC. Atenolol in children with ventricular arrhythmias. Am Heart J 1990;119(6):1312–1316.PubMedCrossRefGoogle Scholar
  21. 21.
    Trippel DL, Gillette PC. Atenolol in children with supraventricular tachycardia. Am J Cardiol 1989;64(3):233–236.PubMedCrossRefGoogle Scholar
  22. 22.
    Buck ML, Wiest D, Gillette PC, Trippel D, Krull J, O’Neal W. Pharmacokinetics and pharmacodynamics of atenolol in children. Clin Pharmacol Ther 1989;46(6):629–633.PubMedGoogle Scholar
  23. 23.
    Frick MH, Luurila O. Double-blind titrated-dose comparison of metoprolol and propranolol in the treatment of angina pectoris. Ann Clin Res 1976;8(6):385–392.PubMedGoogle Scholar
  24. 24.
    Mehta AV, Chidambaram B. Efficacy and safety of intravenous and oral nadolol for supraventricular tachycardia in children. J Am Coll Cardiol 1992;19(3):630–635.PubMedCrossRefGoogle Scholar
  25. 25.
    Mehta AV, Chidambaram B, Rice PJ. Pharmacokinetics of nadolol in children with supraventricular tachycardia. J Clin Pharmacol 1992;32(11):1023–1027.PubMedGoogle Scholar
  26. 26.
    Perry JC, Knilans TK, Marlow D, Denfield SW, Fenrich AL, Friedman RA. Intravenous amiodarone for life-threatening tachyarrhythmias in children and young adults. J Am Coll Cardiol 1993;22(1):95–98.PubMedCrossRefGoogle Scholar
  27. 27.
    Coumel P, Fidelle J. Amiodarone in the treatment of cardiac arrhythmias in children: one hundred thirty-five cases. Am Heart J 1980;100(6 Pt 2):1063–1069.Google Scholar
  28. 28.
    Figa FH, Gow RM, Hamilton RM, Freedom RM. Clinical efficacy and safety of intravenous Amiodarone in infants and children. Am J Cardiol 1994;74(6):573–577.PubMedCrossRefGoogle Scholar
  29. 29.
    Perry JC, Fenrich AL, Hulse JE, Triedman JK, Friedman RA, Lamberti JJ. Pediatric use of intravenous amiodarone: efficacy and safety in critically ill patients from a multicenter protocol. J Am Coll Cardiol 1996;27(5):1246–1250.PubMedCrossRefGoogle Scholar
  30. 30.
    Maragnes P, Tipple M, Fournier A. Effectiveness of oral sotalol for treatment of pediatric arrhythmias. Am J Cardiol 1992;69(8):751–754.PubMedCrossRefGoogle Scholar
  31. 31.
    Pfammatter JP, Paul T, Lehmann C, Kallfelz HC. Efficacy and proarrhythmia of oral sotalol in pediatric patients. J Am Coll Cardiol 1995;26(4):1002–1007.PubMedCrossRefGoogle Scholar
  32. 32.
    Heissenbuttel RH, Bigger JT Jr. Bretylium tosylate: a newly available antiarrhythmic drug for ventricular arrhythmias. Ann Intern Med 1979;91(2):229–238.PubMedGoogle Scholar
  33. 33.
    Ellenbogen KA, Clemo HF, Stambler BS, Wood MA, VanderLugt JT. Efficacy of ibutilide for termination of atrial fibrillation and flutter. Am J Cardiol 1996;78(8A):42–45.PubMedCrossRefGoogle Scholar
  34. 34.
    Epstein ML, Kiel EA, Victorica BE. Cardiac decompensation following verapamil therapy in infants with supraventricular tachycardia. Pediatrics 1985;75(4):737–740.PubMedGoogle Scholar
  35. 35.
    Dougherty AH, Jackman WM, Naccarelli GV, Friday KJ, Dias VC. Acute conversion of paroxysmal supraventricular tachycardia with intravenous diltiazem. IV Diltiazem Study Group. Am J Cardiol 1992;70(6):587–592.PubMedCrossRefGoogle Scholar
  36. 36.
    Overholt ED, Rheuban KS, Gutgesell HP, Lerman BB, DiMarco JP. Usefulness of adenosine for arrhythmias in infants and children. Am J Cardiol 1988;61(4):336–340.PubMedCrossRefGoogle Scholar
  37. 37.
    Stueven HA, Tonsfeldt DJ, Thompson BM, Whitcomb J, Kastenson E, Aprahamian C. Atropine in asystole: human studies. Ann Emerg Med 1984;13(9 Pt 2):815–817.Google Scholar
  38. 38.
    Hoshino K, Ogawa K, Hishitani T, Isobe T, Etoh Y. Successful uses of magnesium sulfate for torsades de pointes in children with long QT syndrome. Pediatr Int 2006;48(2):112–117.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2008

Authors and Affiliations

  • Anne M. Dubin
    • 1
  1. 1.Division of Pediatric CardiologyStanford UniversityPalo AltoUSA

Personalised recommendations